Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Journal Scan / Research · July 31, 2024

Apixaban vs Aspirin According to CHA2DS2-VASc Score in Patients With Subclinical Atrial Fibrillation

Journal of the American College of Cardiology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American College of Cardiology
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA
J Am Coll Cardiol 2024 Jul 23;84(4)354-364, RD Lopes, CB Granger, DM Wojdyla, WF McIntyre, M Alings, T Mani, C Ramasundarahettige, L Rivard, D Atar, DH Birnie, G Boriani, G Amit, P Leong-Sit, C Rinne, GZ Duray, MR Gold, SH Hohnloser, V Kutyifa, J Benezet-Mazuecos, J Cosedis Nielsen, C Sticherling, AP Benz, C Linde, J Kautzner, P Mabo, GH Mairesse, SJ Connolly, JS Healey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading